Skip to content

Ligand Pharmaceuticals

US · LGND #1920 by market cap Listed 1970
286.85 -0.09 -0.03%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.42 Expensive vs history 99th percentile
5-year average 2.80 · #418 of 514 in Biotechnology
P/E ratio 124.01 Expensive vs history 99th percentile
5-year average -1.95 · forward 68.95 · #75 of 77 in Biotechnology
P/S ratio 24.33 Expensive vs history 99th percentile
5-year average 11.29 · forward 17.63 · #225 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Ligand Pharmaceuticals (LGND) 5.74B 115.20 5.97 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value284.08 Economic moatNarrow UncertaintyHigh

Trading 1.0% above Morningstar's fair value estimate.

Fair value

Ligand Pharmaceuticals Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% premium over our quantitative fair value estimate of $284.08 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's lack of profitability weakens our valuation estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's sales yield of 3.8% ranks in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our view that shares are overvalued.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 15.7%, for example, ranks in the bottom 20% globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ligand Pharmaceuticals discussion 0 comments

Add a comment